Confocal analysis of fluorescence-labelled samples obtained at surgery will likely allow for the stratification of breast cancer patients into two groups with substantially different relapse rates on the basis of CD44+/CD24− cell percentage. The gene discussed is CD44; the disease is breast carcinoma.